AEB - Drug names

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/58

encourage image

There's no tags or description

Looks like no tags are added yet.

59 Terms

1
New cards
Memantine
low affinity NMDA receptor antagonist blocking excess stimulation by glutamate, helping treat Alzheimers.
2
New cards
MK-801
high affinity NMDA receptor antagonist not used in humans due to cognitive disruptions (inc. coma) with other severe adverse effects due to lasting antagonist actions.
3
New cards
PCP
illicit moderate affinity NMDA receptor antagonist causing hallucinations.
4
New cards
Ketamine
moderate affinity NMDA receptor antagonist causing anesthesia and sedation.
5
New cards
Benzodiazepine
positive allosteric GABA-A receptor modulator increasing frequnecy of Cl⁻ channels channel opening to enhance GABA CNS inhibition for sedative, anxiolytic, anticonvulsant, and anaesthetic effects.
6
New cards
Donepezil
AChE inhibitor; slows ACh metabolism to increase synaptic levels, slowing cognitive decline in Alzheimer’s and Parkinson's patients. Long acting.
7
New cards
Tacrine
short-acting, reversible inhibition of AChE and BChE associated with vomiting, cramps and liver toxicity. No longer used.
8
New cards
Rivastigmine
reversible inhibition of both AChE and BChE, transdermal patch administration can reduce gastrointestinal effects.
9
New cards
Galantamine
reversible, competitive AChE inhibitor; also positively modulates nicotinic ACh receptors.
10
New cards
Scopolamine
muscarinic receptor antagonist; blocks ACh action in the CNS used to treat nausea and vomiting and can induce memory deficit.
11
New cards
Amantidine
increases dopaminergic activity through several mechanisms to mildly improve motor symptoms ad reduced levadopa-induced dyskinesia.
12
New cards
Nicotine
nicotinic receptor agonist; stimulates dopamine release in the nucleus accumbens associated with pleasure, reward, and addiction - regular exposure can change receptor number and sensitivity.
13
New cards
Haloperidol
D2 dopamine receptor antagonist; decreases D2-mediated hallucinations, delusions, and hyperactivity in schizophrenia and other behavioural disorders. Can cause motor dysfunction.
14
New cards
Schizophrenia
What can D2 dopamine receptor antagonists be used to treat?
15
New cards
L-dopa
amino acid precursor for dopamine, can be given to increase dopamine synthesis to treat Parkinson’s disease.
16
New cards
Carbidopa
aromatic L-amino acid decarboxylase (AADC) inhibitor; reduces breakdown of dopamine precursor L-dopa in blood to increase levels in the brain to treat Parkinson’s disease.
17
New cards
Entacapone
catechol-O-methyl transferase (COMT) inhibitor; reduces metabolism of L-dopa increasing, dopamine levels to treat Parkinson’s disease.
18
New cards
Selegine
monoamine oxidase (MAO) inhibitor; reduced metabolism of dopamine, increasing levels to treat Parkinson’s disease.
19
New cards
Decarboxylase inhibitor
combined with levodopa; inhibits peripheral conversion of levaoopa to dopamine so more may enter the CNS and to reduce peripheral side effects, e.g. carbidopa.
20
New cards
Dopamine (DA) agonist
directly stimulates dopamine receptors, mimicking dopamine’s effects on the striatum; lower potency but effective for longer with fewer dyskinesias, e.g. carbergoline, rotigitine.
21
New cards
Carbergoline, rotigitine
list common dopamine agonists used.
22
New cards
Apomorphine
potent dopamine agonist given by injection or infusion to people with advanced Parkinson’s disease.
23
New cards
Confusion and psychosis, impulse control disorder, drowsiness
List common adverse effects of dopamine agonists.
24
New cards
Tricyclic antidepressants, serotonin/noradrenaline reuptake inhibitors
List 2 drug classes treating depression by inhibiting the reuptake for noradrenaline and serotonin.
25
New cards
Methylphenidate
dopamine and noradrenaline reuptake inhibitor (DAT/NET); increase their synaptic availability to treat ADHD.
26
New cards
Amphetamines
increase dopamine and noradrenaline release and reverse their transportes (DAT/NET); increase CNS stimulation and are used to treat ADHD and narcolepsy.
27
New cards
Blocks serotonin, dopamine, and noradrenaline reuptake
Describe action of cocaine.
28
New cards
Promotes serotonin release, inhibits serotonin transporter
Describe action of MDMA.
29
New cards
Migraine
What can a serotonin receptor agonist be used to treat?
30
New cards
MDMA (ecstasy)
promotes serotonin release and reverse/inhibits SERT, causing a large increase in extracellular serotonin; produces stimulant and empathogenic effects.
31
New cards
Cocaine
blocks serotonin, dopamine, and noradrenaline reuptake transporters (SERT/DAT/NET); increases their synaptic concentrations and produces stimulant effects.
32
New cards
Selective serotonin reuptake inhibitors (SSRIs)
selectively inhibit serotonin reuptake, increasing availability in synaptic cleft; used to treat depression and anxiety, e.g. fluoxetine.
33
New cards
Sumatriptan
selective 5-HT receptor agonist; constricts cranial blood vessels and inhibits trigeminal neuropeptide release to relieve acute migraine.
34
New cards
Clozapine
5-HT and D2 receptor agonist; reduces psychotic symptoms to treat schizophrenia.
35
New cards
Opioids
active opioid receptors; inhibit neurotransmitter release and neuronal activity in pain pathways, producing analgesia, e.g. morphine, endorphins.
36
New cards
Tachykinins
neurokinin receptor activators; promote pain transmission and neurogenic inflammation, e.g. substance P; antagonists can reduce nausea and vomiting.
37
New cards
Cefotaxime or ceftriaxone
empiric antibiotic therapy given to adults and children 2 months or older with suspected bacterial meningitis.
38
New cards
Benzylpenicillin and cefotaxime
empiric antibiotic therapy given to infants under 2 months old with suspected bacterial meningitis.
39
New cards
Benzylpenicillin
added if Listeria monocytogenes is the suspected cause of bacterial meningitis.
40
New cards
Vancomycin
added if antibiotic-resistant Streptococcus pneumoniae is the suspected cause of bacterial meningitis.
41
New cards
Dexamethosone
anti-inflammatory corticosteroid given before or with first antibiotic dose to reduced inflammation-related CNS damage with bacterial meningitis.
42
New cards
Fluoxetine
selective serotonin reuptake inhibitor, increases synaptic serotonin levels to manage depression.
43
New cards
Venlafaxine
serotonin and noradrenaline reuptake inhibitor, increases synaptic serotonin and noradrenaline levels to manage depression.
44
New cards
Lecanemab, solanezumab
monoclonal antibodies targeting soluble Aβ, clearing brain amyloids by creating a peripheral sink.
45
New cards
Donanemab, aducanumab
monoclonal antibodies targeting aggregated/insoluble Aβ, clearing brain amyloids by aiding microglia recognition and breakdown.
46
New cards
Alteplase, tenecteplase
list recombinant tissue plasminogen activators.
47
New cards
Tissue plasminogen activator
converts plasminogen to plasmin, which breaks down fibrin in the clot to restore blood flow in acute ischaemic stroke.
48
New cards
Heparin
anticoagulant given by IV; activates antithrombin III inhibiting activated clotting factors to prevent fibrin formation for a thrombus, often with delayed response.
49
New cards
Warfarin
anticoagulant given orally; inhibits vitamin K recycling to reduce synthesis of clotting factors II (prothrombin), VII, IX, and X to prevent thrombus formation. Requires serial blood test monitoring and dietary adjustment, plus has many drug interactions.
50
New cards
Direct oral anticoagulant (DOAC)
anticoagulant given orally; directly inhibits clotting factors to prevent thrombus formation with reduced risk profile and need for monitoring.
51
New cards
Activates antithrombin III to inhibit clotting factors
describe mechanism of action of heparin.
52
New cards
Inhibits VK recycling for reduced clotting factor synthesis
describe mechanism of action of warfarin.
53
New cards
Inhibits clotting factors
describe mechanism of action for direct oral anticoagulants.
54
New cards
Aspirin
antiplatelet agent that irreversibly inhibits COX-1 to reduce platelet aggregation preventing clot formation and extension given to >80% of ischaemic stroke patients.
55
New cards
Dipyridamole
antiplatelet agent that inhibits phoshodiesterase to reduce clot formation, often combined with aspirin.
56
New cards
Clopidogrel
antiplatelet agent that blocks ADP receptors to reduce platelet aggregation preventing clot formation, often combined with aspirin.
57
New cards
Inhibits COX-1 to reduce platelet aggregation
describe mechanism of action of aspirin.
58
New cards
Inhibits phosphodiesterase to inhibit clot formation
describe mechanism of action of dipyridamole.
59
New cards
Blocks ADP receptors to reduce platelet aggregation
describe mechanism of action of clopidogrel.